Connect

Evidence generation.

Evidence that drives access, reimbursement, and value.

How we help.

We unify HEOR, RWE, biostatistics, and HTA expertise to design evidence strategies that meet payer and clinical expectations. Our work spans planning, generation, and communication, ensuring value is supported across markets and lifecycle stages. With experience in major global HTA processes, we equip clients with evidence that drives access and strengthens competitive positioning. 

  • Design and execute evidence generation strategies that demonstrate value to payers and HTA agencies. 
  • Combine HEOR strategy, RWE for payer access, and biostatistics to strengthen value communication and reimbursement success. 
  • Deliver rigorous, actionable evidence supporting pricing, access, and positioning across the lifecycle. 

Some of our experts.

Meet the experts behind the solutions delivering meaningful impact for our clients.

Eric Faulkner, Partner

Eric is a global executive in evidence development, value demonstration, access, and commercialization with 25+ years of experience. A recognized thought leader in emerging technology evidence, he has supported 750+ peri- and post-approval scenarios.

Partner, Head of Health Economic Modelling

Catriona leads Putnam’s health economic modelling team, specializing in global and HTA-focused models. She has developed models across oncology, chronic diseases, and rare conditions to support rigorous value assessment and payer decisions.

Sylvaine Barbier, Partner, RWE & Biostatistics

Sylvaine leads data analytics within the VPA team and oversees RWE projects, focusing on evidence synthesis and claims database analysis. She develops innovative analytical methods to produce insights from large, complex datasets.

Yemi Oluboyede, Partner, Head of PRO & Patient Preference Studies

Yemi leads the patient-reported outcomes and preference elicitation team, partnering with clients to translate patient insight into impactful evidence generation, underpinned by deep scientific expertise in quality-of-life measurement and valuation with extensive HTA experience across a wide range of therapeutic areas.

Clement Francois, Partner, HTA & Market Access Operations

Clement leads the HTA and Market Access Operations team, advising biopharma from early asset planning through launch. He brings deep HEOR, HTA, and market access experience, including 15 years leading global HEOR teams in industry.

Simon Pannett, Partner, HTA & Market Access

Simon is a seasoned market access leader advising clients from asset strategy through peak sales. He has delivered numerous HTAs, negotiations, and pricing strategies across hematology, oncology, ophthalmology, neurology, and rare diseases.

Yoshi Onishi, Principal, Japan HTA & Market Access

Yoshie manages Japan-focused projects including database analysis, cost-effectiveness studies, clinical outcome assessment, and HTA submissions. Her expertise spans biostatistics, epidemiology, healthcare policy, and pharmaceutical market access.

Erika Ray, Principal

Erika helps clients develop strategies for pipeline agents, assess commercial opportunities, and address access topics across oncology, vaccine-preventable diseases, immunology, neurology, and rare diseases.

Lori Klein, Partner, Medical and Scientific Affairs Practice Lead

Lori’s expertise spans stakeholder engagement, center-of-excellence profiling, organizational design, strategic medical launches, integrated evidence planning, omnichannel strategy, and digital health platforms including digital therapeutics, AI, and software as a medical device.

Insights & latest.

Access the most up-to-date health and life sciences insights and resources. 

View all resources

Connect.

Let’s discuss how we can help you. 

* indicates a required field